Evonik Shares Poised for Recovery as Core Business Dynamics Shift

Barclays upgrades Evonik to Overweight, citing supply disruptions in Asia that are reversing price pressure on methionine and boosting profit forecasts for the specialty chemicals group.

A significant reassessment is underway for Evonik, the Essen-based specialty chemicals group, driven by unexpected geopolitical developments. Factors once viewed by analysts as vulnerabilities are rapidly transforming into potential profit drivers, prompting a major investment bank to revise its stance on the company's equity.

Barclays Upgrades on Supply-Driven Optimism

In a notable move, analysts at Barclays have upgraded their rating on Evonik shares from 'Equal Weight' to 'Overweight'. Concurrently, they have raised their price target from 16 to 17 euros. This renewed optimism centers primarily on the market for methionine, a crucial animal feed amino acid. Previous expectations of price normalization and margin pressure are being upended by current events.

Logistical disruptions in the Strait of Hormuz and tight raw material availability in Asia are reversing that trend. The supply constraints have become so pronounced that Evonik was forced to declare force majeure for its production facility in Singapore due to missing key precursors. Should Asian supply continue to tighten, Western buyers are likely to increasingly source from production sites outside the region, providing substantial support to selling prices in Europe and the United States.

Barclays consequently anticipates a positive pricing effect, leading it to increase its EBITDA forecast for 2026 to 1.89 billion euros. This improved operational outlook arrives at a critical juncture for the stock. Closing at 13.91 euros on Friday, the shares remain down approximately 35% for the year. A Relative Strength Index (RSI) reading of 23.3 further indicates the stock is in technically oversold territory.

Structural Advantages and Strategic Focus

Beyond the favorable shift in the methionine market, Evonik benefits from structural advantages. Unlike more broadly diversified basic chemical competitors, the company is less exposed to the impact of high natural gas prices. A further potential lever for valuation lies in the group's planned strategic overhaul.

Management has ruled out major acquisitions until 2027, choosing instead to focus strictly on debt reduction. The planned divestment of the infrastructure service provider Syneqt could generate significant funds. This division generates an operating result of around 200 million euros. Market observers suggest this unit could command a more attractive valuation in a sale than what is currently reflected in the group's overall market capitalization.

Investors will gain clarity on whether price increases for key products like MetAMINO are translating to the financial statements on May 8. On that date, Evonik is scheduled to present its results for the first quarter of 2026. Until then, the trajectory of global supply chains will remain the decisive factor for any sustained share price recovery.